Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study.


Journal

Journal of cardiovascular computed tomography
ISSN: 1876-861X
Titre abrégé: J Cardiovasc Comput Tomogr
Pays: United States
ID NLM: 101308347

Informations de publication

Date de publication:
Historique:
received: 20 09 2019
revised: 28 02 2020
accepted: 23 03 2020
pubmed: 22 6 2020
medline: 7 4 2021
entrez: 22 6 2020
Statut: ppublish

Résumé

High-risk coronary atherosclerosis features evaluated coronary CT angiography (CCTA) were suggested to have a prognostic role. The present study aimed to evaluate the association of circulating biomarkers with high-risk plaque features assessed by CCTA. A consecutive cohort of subjects who underwent CCTA because of suspected CAD was screened for inclusion in the CAPIRE study. Based on risk factors (RF) burden patients were defined as having a low clinical risk (0-1 RF with the exclusion of patients with diabetes mellitus as single RF) or an high clinical risk (≥3 RFs). In all patients, measurement of inflammatory biomarkers and CCTA analysis focused on high-risk plaque features were performed. Univariate and multivariate logistic regression analysis were used to evaluate the relationship between clinical and biological variables with CCTA advanced plaque features. 528 patients were enrolled in CAPIRE study. Older age and male sex appeared to be predictors of qualitative high-risk plaque features and associated with the presence of elevated total, non-calcified and low-attenuation plaque volume. Among circulating biomarkers only hs-CRP was found to be associated with qualitative high-risk plaque features (OR 2.02, p = 0.004 and 2.02, p = 0.012 for LAP and RI > 1.1, respectively) with borderline association with LAP-Vol (OR 1.52, p = 0.076); HbA1c and PTX-3 resulted to be significantly associated with quantitative high-risk plaque features (OR 1.71, p = 0.003 and 1.04, p = 0.002 for LAP-Vol, respectively). Our results support the association between inflammatory biomarkers (hs-CRP, PTX- 3), HbA1c and high-risk atherosclerotic features detected by CCTA. Male sex and older age are significant predictors of high-risk atherosclerosis.

Sections du résumé

BACKGROUND BACKGROUND
High-risk coronary atherosclerosis features evaluated coronary CT angiography (CCTA) were suggested to have a prognostic role. The present study aimed to evaluate the association of circulating biomarkers with high-risk plaque features assessed by CCTA.
METHODS METHODS
A consecutive cohort of subjects who underwent CCTA because of suspected CAD was screened for inclusion in the CAPIRE study. Based on risk factors (RF) burden patients were defined as having a low clinical risk (0-1 RF with the exclusion of patients with diabetes mellitus as single RF) or an high clinical risk (≥3 RFs). In all patients, measurement of inflammatory biomarkers and CCTA analysis focused on high-risk plaque features were performed. Univariate and multivariate logistic regression analysis were used to evaluate the relationship between clinical and biological variables with CCTA advanced plaque features.
RESULTS RESULTS
528 patients were enrolled in CAPIRE study. Older age and male sex appeared to be predictors of qualitative high-risk plaque features and associated with the presence of elevated total, non-calcified and low-attenuation plaque volume. Among circulating biomarkers only hs-CRP was found to be associated with qualitative high-risk plaque features (OR 2.02, p = 0.004 and 2.02, p = 0.012 for LAP and RI > 1.1, respectively) with borderline association with LAP-Vol (OR 1.52, p = 0.076); HbA1c and PTX-3 resulted to be significantly associated with quantitative high-risk plaque features (OR 1.71, p = 0.003 and 1.04, p = 0.002 for LAP-Vol, respectively).
CONCLUSIONS CONCLUSIONS
Our results support the association between inflammatory biomarkers (hs-CRP, PTX- 3), HbA1c and high-risk atherosclerotic features detected by CCTA. Male sex and older age are significant predictors of high-risk atherosclerosis.

Identifiants

pubmed: 32563713
pii: S1934-5925(20)30128-3
doi: 10.1016/j.jcct.2020.03.005
pii:
doi:

Substances chimiques

Biomarkers 0
Glycated Hemoglobin A 0
Serum Amyloid P-Component 0
hemoglobin A1c protein, human 0
PTX3 protein 148591-49-5
C-Reactive Protein 9007-41-4

Types de publication

Comparative Study Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

73-80

Investigateurs

A Maseri (A)
D Andreini (D)
S Berti (S)
M Canestrari (M)
G Casolo (G)
D Gabrielli (D)
R Latini (R)
M Magnoni (M)
P Marraccini (P)
S Masson (S)
T Moccetti (T)
M G Modena (MG)
D Andreini (D)
G Pontone (G)
S Masson (S)
F Gaspari (F)
S Ferrari (S)
A Cannata (A)
N Stucchi (N)
M Fois (M)
R Bernasconi (R)
G Balconi (G)
T Vago (T)
T Letizia (T)
B Bottazzi (B)
R Leone (R)
I Suliman (I)
M Sommaruga (M)
P Gremigni (P)
R Olivieri (R)
L Pennacchietti (L)
M Magnacca (M)
M G Rossi (MG)
E Pasotti (E)
T Moccetti (T)
A Clemente (A)
D Andreini (D)
G Pontone (G)
S Mushtaq (S)
E Mauro (E)
R Rossi (R)
F Pigazzani (F)
L Faggioni (L)
M Ciardetti (M)
M Puppato (M)

Informations de copyright

Copyright © 2020 Society of Cardiovascular Computed Tomography. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest Daniele Andreini declares the following conflict of interest: speaker bureau for GE Healthcare, research grant (to the Institution) from GE Healthcare and Bracco. The other authors have nothing to declare. Gianluca Pontone declares the following conflict of interest: Institutional fee as speaker and/or research grant from GE Helthcare, Bracco, Bayer, Medtronic, Heartflow.

Auteurs

Edoardo Conte (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Italy. Electronic address: daniele.andreini@ccfm.it.

Marco Magnoni (M)

Heart Care Foundation Onlus, Florence, Italy.

Serge Masson (S)

Department of Cardiovascular Research, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Saima Mushtaq (S)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Sergio Berti (S)

FTGM - Stabilimento di Massa, UO Adult Cardiology, Massa, Italy.

Mauro Canestrari (M)

Department of Cardiology, Santa Croce Hospital, Fano, Italy.

Giancarlo Casolo (G)

Department of Cardiology, Nuovo Ospedale Versilia, Lido di Camaiore, Italy.

Domenico Gabrielli (D)

Department of Cardiology, Ospedale Civile A. Murri, Fermo, Italy.

Roberto Latini (R)

Department of Cardiovascular Research, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Paolo Marraccini (P)

IFC CNR - Fondazione Toscana G. Monasterio, S.A. Emodinamica, Pisa, Italy.

Tiziano Moccetti (T)

SRC, Cardiocentro Ticino, Lugano, Switzerland.

Maria Grazia Modena (MG)

Department of Cardiology, Ospedale Policlinico, Modena, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marco Gorini (M)

ANMCO Research Center, Heart Care Foundation Onlus, Florence, Italy.

Aldo P Maggioni (AP)

ANMCO Research Center, Heart Care Foundation Onlus, Florence, Italy.

Attilio Maseri (A)

Heart Care Foundation Onlus, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH